168 related articles for article (PubMed ID: 38501850)
21. A Case Report of Successful Use of Twice-Daily Letermovir in the Treatment of Resistant Cytomegalovirus in a Small Bowel Transplant Recipient.
Joharji H; Alaidaros F; Koujan H; Hamad A; Almaghrabi RS; Zidan A; Broering D; Al-Jedai A
Transplant Proc; 2022; 54(6):1679-1681. PubMed ID: 35842318
[TBL] [Abstract][Full Text] [Related]
22. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
Torres-Madriz G; Boucher HW
Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557
[TBL] [Abstract][Full Text] [Related]
23. Antivirals for cytomegalovirus infection in neonates and infants: focus on pharmacokinetics, formulations, dosing, and adverse events.
Marshall BC; Koch WC
Paediatr Drugs; 2009; 11(5):309-21. PubMed ID: 19725597
[TBL] [Abstract][Full Text] [Related]
24. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy.
Kalil AC; Freifeld AG; Lyden ER; Stoner JA
PLoS One; 2009; 4(5):e5512. PubMed ID: 19436751
[TBL] [Abstract][Full Text] [Related]
25. Resistant Cytomegalovirus Infection in Solid-organ Transplantation: Single-center Experience, Literature Review of Risk Factors, and Proposed Preventive Strategies.
Majeed A; Latif A; Kapoor V; Sohail A; Florita C; Georgescu A; Zangeneh T
Transplant Proc; 2018 Dec; 50(10):3756-3762. PubMed ID: 30586840
[TBL] [Abstract][Full Text] [Related]
26. Cytomegalovirus prophylaxis and treatment following bone marrow transplantation.
Tsinontides AC; Bechtel TP
Ann Pharmacother; 1996 Nov; 30(11):1277-90. PubMed ID: 8913411
[TBL] [Abstract][Full Text] [Related]
27. Letermovir and Maribavir for the Treatment and Prevention of Cytomegalovirus Infection in Solid Organ and Stem Cell Transplant Recipients.
Imlay HN; Kaul DR
Clin Infect Dis; 2021 Jul; 73(1):156-160. PubMed ID: 33197929
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Antiviral Agents in Preventing Allograft Rejection Following CMV Prophylaxis in High-Risk Kidney Transplantation: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Ruenroengbun N; Sapankaew T; Chaiyakittisopon K; Phoompoung P; Ngamprasertchai T
Front Cell Infect Microbiol; 2022; 12():865735. PubMed ID: 35433502
[TBL] [Abstract][Full Text] [Related]
29. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice.
Razonable RR; Humar A
Clin Transplant; 2019 Sep; 33(9):e13512. PubMed ID: 30817026
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
[TBL] [Abstract][Full Text] [Related]
31. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
[TBL] [Abstract][Full Text] [Related]
32. Maribavir: a novel antiviral agent with activity against cytomegalovirus.
Trofe J; Pote L; Wade E; Blumberg E; Bloom RD
Ann Pharmacother; 2008 Oct; 42(10):1447-57. PubMed ID: 18698013
[TBL] [Abstract][Full Text] [Related]
33. Use of Cidofovir for Cytomegalovirus Disease Refractory to Ganciclovir in Solid Organ Recipients.
Bonatti H; Sifri CD; Larcher C; Schneeberger S; Kotton C; Geltner C
Surg Infect (Larchmt); 2017; 18(2):128-136. PubMed ID: 27849440
[TBL] [Abstract][Full Text] [Related]
34. Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts.
Reusser P
Expert Opin Investig Drugs; 2001 Sep; 10(9):1745-53. PubMed ID: 11772283
[TBL] [Abstract][Full Text] [Related]
35. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection.
Avery RK; Bolwell BJ; Yen-Lieberman B; Lurain N; Waldman WJ; Longworth DL; Taege AJ; Mossad SB; Kohn D; Long JR; Curtis J; Kalaycio M; Pohlman B; Williams JW
Bone Marrow Transplant; 2004 Dec; 34(12):1071-5. PubMed ID: 15489872
[TBL] [Abstract][Full Text] [Related]
36. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
[TBL] [Abstract][Full Text] [Related]
37. Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium.
Khawaja F; Spallone A; Kotton CN; Chemaly RF
Clin Microbiol Infect; 2023 Jan; 29(1):44-50. PubMed ID: 35843567
[TBL] [Abstract][Full Text] [Related]
38. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes.
Eid AJ; Arthurs SK; Deziel PJ; Wilhelm MP; Razonable RR
Clin Transplant; 2008; 22(2):162-70. PubMed ID: 18339135
[TBL] [Abstract][Full Text] [Related]
39. Valganciclovir: new preparation. CMV retinitis: a simpler, oral treatment.
Prescrire Int; 2003 Aug; 12(66):133-5. PubMed ID: 12906021
[TBL] [Abstract][Full Text] [Related]
40. Factors Associated With Genotypic Resistance and Outcome Among Solid Organ Transplant Recipients With Refractory Cytomegalovirus Infection.
Tamzali Y; Pourcher V; Azoyan L; Ouali N; Barrou B; Conti F; Coutance G; Gay F; Tourret J; Boutolleau D
Transpl Int; 2023; 36():11295. PubMed ID: 37398559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
